Rethinking How We Track and Treat Cancer

Labcorp, Rebecca Previs, Michelle Green, genomics, ASCO, HER2, HER3, MRD, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, ctDNA, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen

Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness

Welcome back to the Pharmaverse, where we speak to the greatest voices in Pharma, to learn from their leadership and incredible careers! In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Paul Romness, CEO of OS Therapies. The conversation delves into the inspiring sto…

Nov 18^th • 25 mins listen

Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care

ONS members Kristin Daly, MSN, ANP-BC, AOCNP®, medical oncology nurse practitioner at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, MO, and Jessica Pforr, RN, AOCNP®, nurse practitioner at Mon Medical Center in Morgantown, WV, join Stephanie Jardine,…

Mar 29^th • 38 mins listen

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…

Mar 30^th • 47 mins listen

Oncology Pharmacology 2023: Today’s Treatments and Tomorrow’s Breakthroughs

CDER, FDA, Nurses, biomarker, immunomodulatory

Highlights From Today’s Episode “Full approval through the Center for Drug Evaluation and Research (CDER) and FDA means that those drugs have gone through the laboratory testing, human clinical trial testing, and very extensive clinical trials to make sure that they are effective and th…

Mar 30^th • 53 mins listen